GO:0009083 branched-chain amino acid catabolic process: Metabolic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009083 describes the biochemical breakdown of the three branched-chain amino acids (BCAAs) isoleucine, leucine, and valine.
• The pathway is initiated by cytosolic or mitochondrial branched-chain aminotransferases (BCAT1/BCAT2) and completed by the mitochondrial branched-chain alpha-ketoacid dehydrogenase complex (BCKDH) [1, 4].
• Impaired BCAA catabolism leads to accumulation of BCAAs and their toxic metabolites, which is associated with heart failure, insulin resistance, obesity, and type 2 diabetes [1, 2, 3, 5].
• BCAA catabolic flux modulates immune cell polarization, inflammation, and epigenetic states, linking metabolism to gene regulation [7, 8].
• Dysregulated BCAA catabolism exacerbates myocardial ischemia/reperfusion injury and diabetic retinopathy through specific signaling pathways [6, 8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect causal roles of BCAA catabolic enzymes in disease.
Description
The branched-chain amino acid (BCAA) catabolic process, annotated as GO:0009083, encompasses the enzymatic reactions that degrade the essential amino acids leucine, isoleucine, and valine. This pathway is critical for energy production, nitrogen disposal, and the generation of metabolic intermediates that feed into the tricarboxylic acid cycle and lipogenesis [1, 4]. Unlike many amino acid degradation pathways, BCAA catabolism is tightly regulated and tissue-specific, with the highest activity in skeletal muscle, heart, liver, and adipose tissue. Dysregulation of BCAA catabolism has emerged as a hallmark of metabolic disease. Elevated circulating BCAAs and their catabolic intermediates are strongly associated with obesity, insulin resistance, and type 2 diabetes, and can predict future diabetes risk [2, 3]. In the heart, a defect in BCAA catabolism promotes heart failure by impairing mitochondrial function and increasing oxidative stress. Moreover, BCAA catabolic enzymes influence immune cell function and inflammation, with recent studies showing that BCAA catabolism promotes M2 macrophage polarization and that BCAT1 activation epigenetically drives inflammation in diabetic retinopathy [7, 8]. For researchers, GO:0009083 provides a framework to study how genetic and environmental factors alter BCAA flux and contribute to disease. Understanding this pathway at the molecular level is essential for developing targeted therapies, and CRISPR-based cell models offer powerful tools to dissect the causal roles of individual enzymes and regulatory nodes [4, 6].
branched-chain amino acid catabolic process At A Glance
| GO ID | GO:0009083 |
|---|---|
| GO term | branched-chain amino acid catabolic process |
| Ontology | biological_process |
| Synonym | branched chain family amino acid breakdown; branched chain family amino acid catabolic process; branched chain family amino acid catabolism; branched chain family amino acid degradation |
| Major function | Degradation of leucine, isoleucine, and valine to generate energy and metabolic intermediates |
| Key enzymes | BCAT1, BCAT2, BCKDHA, BCKDHB, DBT, DLD, and downstream enzymes |
| Subcellular location | Cytosol (transamination) and mitochondria (oxidative decarboxylation and subsequent steps) |
| Pathway relevance | Linked to insulin resistance, heart failure, obesity, type 2 diabetes, and immune regulation |
What Is GO:0009083?
GO:0009083, branched-chain amino acid catabolic process, is defined as the chemical reactions and pathways resulting in the breakdown of amino acids containing a branched carbon skeleton, specifically isoleucine, leucine, and valine. This process includes transamination, oxidative decarboxylation, and subsequent steps that convert these amino acids into acetyl-CoA, acetoacetate, and succinyl-CoA, which can enter central metabolic pathways [1, 4].
Why Is branched-chain amino acid catabolic process Important in Cell Biology?
The branched-chain amino acid catabolic process is a central node in metabolic regulation, and its dysfunction is causally implicated in major human diseases. Elevated BCAA levels and impaired catabolic flux are among the strongest metabolic signatures of insulin resistance and type 2 diabetes, and they contribute to disease progression through mechanisms involving mitochondrial dysfunction, lipotoxicity, and inflammation [2, 3, 5]. In the heart, a defect in BCAA catabolism promotes heart failure by disrupting mitochondrial energy metabolism and increasing oxidative stress. BCAA catabolism also modulates immune responses, with recent evidence linking it to macrophage polarization and inflammatory signaling in diabetic retinopathy [7, 8]. Thus, understanding GO:0009083 is essential for developing therapeutic strategies targeting metabolic and inflammatory diseases.
• Provides a major route for disposal of the essential BCAAs leucine, isoleucine, and valine, which cannot be synthesized de novo in humans.
• Supplies acetyl-CoA and succinyl-CoA for the TCA cycle, contributing to energy homeostasis during fasting and exercise [1, 5].
• Dysregulation leads to accumulation of BCAAs and branched-chain ketoacids, which are toxic and contribute to insulin resistance [2, 3].
• Impaired BCAA catabolism is a hallmark of heart failure and contributes to myocardial ischemia/reperfusion injury [1, 6].
• BCAA catabolic enzymes regulate immune cell function, including M2 macrophage polarization and inflammatory responses.
• BCAT1 activation in diabetic retinopathy links BCAA metabolism to epigenetic regulation of inflammation.
• The pathway is a potential therapeutic target for obesity, type 2 diabetes, and cardiovascular disease [4, 5].
• Genetic variants in BCAA catabolic genes influence circulating BCAA levels and disease risk.
• BCAA catabolism intersects with mTOR signaling and insulin action, creating a two-way street in metabolic regulation.
• CRISPR-based models enable precise dissection of enzyme-specific contributions to disease phenotypes [4, 6].
What Happens During branched-chain amino acid catabolic process?
Transamination by BCAT enzymes
In simple terms: The first step is a swap that removes the amino group from BCAAs, turning them into ketoacids.
The catabolism of BCAAs begins with reversible transamination of leucine, isoleucine, and valine to their corresponding branched-chain alpha-ketoacids (BCKAs). This reaction is catalyzed by branched-chain aminotransferases: BCAT1 (cytosolic) and BCAT2 (mitochondrial). BCAT1 is primarily expressed in the brain and peripheral tissues, while BCAT2 is highly expressed in skeletal muscle, heart, and kidney [1, 4]. This step is essential for nitrogen disposal and generates glutamate, which can be used for other metabolic processes. Dysregulation of BCAT enzymes alters BCAA flux and has been linked to metabolic disease and inflammation.
Oxidative decarboxylation by the BCKDH complex
In simple terms: The ketoacids are then irreversibly broken down by a large enzyme complex, committing them to full degradation.
The rate-limiting step of BCAA catabolism is the oxidative decarboxylation of BCKAs to branched-chain acyl-CoA derivatives, catalyzed by the mitochondrial branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex. This multienzyme complex consists of three catalytic components: BCKDHA (E1 alpha), BCKDHB (E1 beta), DBT (E2), and DLD (E3), along with a regulatory kinase (BCKDK) and phosphatase (PPM1K). BCKDH activity is tightly regulated by phosphorylation/dephosphorylation, which controls flux through the pathway [1, 4]. Defects in BCKDH cause maple syrup urine disease, and reduced activity contributes to BCAA accumulation in heart failure and diabetes [1, 5].
Downstream oxidation and acyl-CoA dehydrogenation
In simple terms: After the committed step, the acyl-CoA products are further oxidized to generate energy and other metabolites.
The branched-chain acyl-CoA derivatives undergo a series of beta-oxidation-like reactions. For leucine, the product is acetoacetate and acetyl-CoA; for isoleucine, acetyl-CoA and succinyl-CoA; and for valine, succinyl-CoA. These reactions involve enzymes such as isovaleryl-CoA dehydrogenase (IVD), short/branched chain acyl-CoA dehydrogenase (ACADSB), and 3-methylcrotonyl-CoA carboxylase (MCCC1/MCCC2). The final products enter the TCA cycle or ketogenesis, linking BCAA catabolism to energy production and lipid synthesis [1, 4]. Impaired downstream steps can cause organic acidurias and contribute to metabolic dysfunction.
Tissue-specific regulation and metabolic integration
In simple terms: Different tissues handle BCAAs differently, and the pathway is turned up or down based on nutritional and hormonal signals.
BCAA catabolism is highly tissue-specific. Skeletal muscle expresses high levels of BCAT2 and BCKDH and is a major site of BCAA oxidation, especially during exercise and fasting. The heart relies on BCAA catabolism for energy, and its impairment leads to heart failure. In adipose tissue, BCAA catabolism is regulated by insulin and contributes to systemic BCAA clearance. The liver has low BCKDH activity but plays a role in BCAA uptake and release. Hormonal signals such as insulin and glucagon, as well as nutrient availability, modulate enzyme expression and activity, integrating BCAA catabolism with whole-body energy homeostasis [3, 5].
Regulation by BCKDK and PPM1K
In simple terms: A kinase and a phosphatase act as a switch to turn the BCKDH complex off and on.
The activity of the BCKDH complex is primarily controlled by reversible phosphorylation. BCKDK (branched-chain ketoacid dehydrogenase kinase) phosphorylates and inactivates BCKDHA, while PPM1K (protein phosphatase, Mg2+/Mn2+ dependent 1K) dephosphorylates and activates it. This regulatory mechanism allows rapid adaptation of BCAA catabolic flux to changes in energy status and substrate availability [1, 4]. Dysregulation of BCKDK or PPM1K alters BCAA catabolism and has been implicated in metabolic diseases, including insulin resistance and heart failure [1, 5].
Key Genes Involved in GO:0009083 branched-chain amino acid catabolic process
The following genes encode key enzymes and regulators of the branched-chain amino acid catabolic process, and their roles are supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BCAT1 | Cytosolic branched-chain aminotransferase; catalyzes reversible transamination of BCAAs | Linked to inflammation, diabetic retinopathy, and cancer metabolism |
| BCAT2 | Mitochondrial branched-chain aminotransferase; major isoform in muscle and heart | Essential for BCAA oxidation; implicated in insulin resistance and heart failure [1, 5] |
| BCKDHA | E1 alpha subunit of BCKDH complex; catalyzes oxidative decarboxylation | Mutations cause maple syrup urine disease; reduced activity in heart failure |
| BCKDHB | E1 beta subunit of BCKDH complex | Required for BCKDH activity; defects cause maple syrup urine disease |
| DBT | Dihydrolipoamide branched chain transacylase E2; core of BCKDH complex | Mutations cause maple syrup urine disease; target for metabolic studies |
| DLD | Dihydrolipoamide dehydrogenase E3; shared subunit of BCKDH and other complexes | Defects cause E3 deficiency; important for mitochondrial metabolism |
| BCKDK | BCKDH kinase; phosphorylates and inactivates BCKDHA | Regulates BCAA catabolic flux; linked to metabolic disease [1, 5] |
| PPM1K | BCKDH phosphatase; activates BCKDH by dephosphorylation | Loss of function impairs BCAA catabolism; associated with metabolic disorders |
| IVD | Isovaleryl-CoA dehydrogenase; catalyzes leucine degradation step | Defects cause isovaleric acidemia; model for organic acidurias |
| ACADSB | Short/branched chain acyl-CoA dehydrogenase; involved in isoleucine and valine catabolism | Mutations cause 2-methylbutyryl-CoA dehydrogenase deficiency |
| MCCC1 | Methylcrotonoyl-CoA carboxylase alpha subunit; leucine degradation | Defects cause 3-methylcrotonyl-CoA carboxylase deficiency |
| MCCC2 | Methylcrotonoyl-CoA carboxylase beta subunit; leucine degradation | Defects cause 3-methylcrotonyl-CoA carboxylase deficiency |
| HMGCL | 3-hydroxy-3-methylglutaryl-CoA lyase; leucine degradation | Defects cause HMG-CoA lyase deficiency; links to ketogenesis |
| AUH | 3-methylglutaconyl-CoA hydratase; leucine degradation | Defects cause 3-methylglutaconic aciduria type I |
| SLC7A5 | L-type amino acid transporter; imports BCAAs into cells | Regulates intracellular BCAA availability for catabolism |
| SLC3A2 | Heavy chain of amino acid transporter; partners with SLC7A5 | Modulates BCAA uptake and mTOR signaling |
| mTOR | Serine/threonine kinase; senses BCAA levels and regulates metabolism | Central to BCAA signaling and insulin resistance |
| GCN2 | EIF2AK4; amino acid sensor kinase; activated by BCAA deficiency | Mediates integrated stress response in BCAA imbalance |
How Is branched-chain amino acid catabolic process Regulated?
The branched-chain amino acid catabolic process is regulated at multiple levels. The rate-limiting BCKDH complex is controlled by reversible phosphorylation via BCKDK and PPM1K, allowing rapid adaptation to energy status [1, 4]. Hormonal signals such as insulin suppress BCAA catabolism in adipose tissue and liver, while glucagon and fasting promote it [3, 5]. Nutrient sensors including mTOR and GCN2 respond to BCAA levels and modulate protein synthesis and the integrated stress response [3, 6]. Transcriptional regulation of BCAT1, BCAT2, and BCKDH subunits by transcription factors such as PPAR-alpha further integrates BCAA catabolism with lipid metabolism. In immune cells, BCAA catabolism is linked to epigenetic regulation and macrophage polarization [7, 8].
branched-chain amino acid catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCKDHA | Heart failure; maple syrup urine disease | Cardiomyocyte-specific knockout; point mutation knock-in |
| BCAT1 | Diabetic retinopathy; inflammation | Retinal cell knockout; overexpression; point mutation |
| BCAT2 | Insulin resistance; obesity | Skeletal muscle-specific knockout; overexpression |
| BCKDK | Metabolic syndrome; heart failure | Knockout; kinase-dead point mutation knock-in |
| PPM1K | Type 2 diabetes; BCAA accumulation | Liver-specific knockout; overexpression |
Heart failure and myocardial ischemia/reperfusion injury
Defective BCAA catabolism promotes heart failure by impairing mitochondrial energy production and increasing oxidative stress. In mouse models, loss of BCKDH activity leads to BCAA accumulation and cardiac dysfunction. During myocardial ischemia/reperfusion, elevated BCAAs exacerbate injury via the GCN2/ATF6/PPAR-alpha pathway, enhancing fatty acid oxidation and oxidative damage. These findings suggest that restoring BCAA catabolic flux could be cardioprotective.
Obesity, insulin resistance, and type 2 diabetes
Elevated circulating BCAAs and their catabolic intermediates are strongly associated with obesity and insulin resistance, and can predict future type 2 diabetes [2, 3]. Impaired BCAA catabolism in adipose tissue and liver contributes to systemic BCAA accumulation, which in turn activates mTOR and disrupts insulin signaling [3, 5]. The relationship is bidirectional: insulin resistance also suppresses BCAA catabolism, creating a vicious cycle. Therapeutic strategies targeting BCAA catabolism are under investigation for metabolic diseases [4, 5].
Diabetic retinopathy and inflammation
BCAT1 activation reprograms BCAA metabolism and epigenetically promotes inflammation in diabetic retinopathy. In retinal cells, BCAT1 upregulation increases BCAA catabolism and alters histone methylation, leading to inflammatory gene expression. This links BCAA catabolism to epigenetic regulation and suggests that BCAT1 inhibitors may have therapeutic potential in diabetic retinopathy.
Immune regulation and macrophage polarization
BCAA catabolism promotes M2 macrophage polarization, which is important for tissue repair and resolution of inflammation. Enhanced BCAA catabolic flux in macrophages supports oxidative metabolism and anti-inflammatory phenotypes. Dysregulation of this pathway may contribute to chronic inflammatory diseases, and targeting BCAA catabolism could modulate immune responses.
From branched-chain amino acid catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of BCKDHA impair cardiac function? | Cardiomyocyte-specific BCKDHA knockout mouse or human iPSC-derived cardiomyocytes |
| Does BCAT1 activation promote inflammation in diabetic retinopathy? | Retinal pigment epithelial cells with BCAT1 overexpression or knockout |
| Does a point mutation in BCKDK alter BCAA flux? | Knock-in of kinase-dead BCKDK in cell lines or mice |
| Can overexpression of PPM1K restore BCAA catabolism? | Lentiviral overexpression in hepatocytes or adipocytes |
| What is the role of BCAT2 in skeletal muscle insulin sensitivity? | Muscle-specific BCAT2 knockout mice or C2C12 myotubes |
| Does BCAA catabolism regulate macrophage polarization? | Bone marrow-derived macrophages with CRISPR knockout of BCKDHA or BCAT1 |
How to Study the branched-chain amino acid catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of BCAAs and catabolic intermediates | Assessing pathway activity in cells and tissues |
| 13C-BCAA tracing | Flux through catabolic pathway | Determining metabolic fate of BCAAs |
| BCKDH activity assay | Enzyme complex activity | Validating genetic models of BCAA catabolism |
| Western blot | Protein expression and phosphorylation | Measuring BCKDHA phosphorylation status |
| RNA-seq | Transcriptional changes in BCAA catabolic genes | Identifying regulatory mechanisms |
| CRISPR knockout screen | Genes required for BCAA catabolism | Discovering novel pathway regulators |
| Immunofluorescence | Subcellular localization of enzymes | Studying mitochondrial vs cytosolic distribution |
| Seahorse assay | Mitochondrial respiration | Assessing metabolic impact of BCAA catabolism |
Metabolomics and flux analysis
Quantification of BCAAs and their catabolic intermediates (e.g., branched-chain ketoacids, acyl-carnitines) by mass spectrometry is essential to assess pathway activity. Stable isotope tracing with 13C-labeled BCAAs allows measurement of flux through the pathway in cells and animal models [1, 2, 5].
Enzyme activity assays
BCKDH complex activity can be measured in tissue lysates by monitoring the decarboxylation of radiolabeled alpha-ketoisovalerate or by spectrophotometric assays. BCAT activity is measured by transamination reactions. These assays are critical for validating genetic models [1, 4].
Gene expression and protein analysis
RNA-seq and quantitative PCR can assess expression of BCAA catabolic genes. Western blotting and immunoprecipitation are used to measure protein levels and phosphorylation status of BCKDHA, which reflects BCKDH activity [1, 5].
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that modulate BCAA catabolism or sensitivity to BCAA restriction. Focused screens targeting metabolic enzymes can reveal novel regulators of the pathway [4, 6].
How CRISPR Can Be Used to Study GO:0009083 branched-chain amino acid catabolic process
Knockout
CRISPR knockout of BCAA catabolic genes (e.g., BCAT1, BCAT2, BCKDHA, BCKDK) in cell lines or primary cells allows researchers to determine their causal role in metabolic and inflammatory phenotypes. For example, BCKDHA knockout in cardiomyocytes can model heart failure-related metabolic defects [1, 4].
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to alter catalytic activity or phosphorylation sites. For instance, knock-in of a kinase-dead BCKDK mutation can reveal the importance of BCKDH phosphorylation in metabolic regulation [1, 4].
Knock-in
Knock-in of tagged versions of BCAA catabolic enzymes (e.g., FLAG-BCAT1) enables immunoprecipitation and interaction studies. Knock-in of reporter genes under the control of endogenous promoters can track pathway activity in real time [4, 8].
Overexpression
Overexpression of BCAA catabolic enzymes such as PPM1K or BCAT2 can enhance pathway flux and rescue metabolic defects. Conversely, overexpression of BCKDK can suppress catabolism. These models are useful for testing therapeutic hypotheses [1, 5].
How EDITGENE Supports branched-chain amino acid catabolic process Research
Researchers studying branched-chain amino acid catabolic process-related genes often need to determine whether a candidate gene is causally involved in metabolic dysfunction, inflammation, or disease progression. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes in the BCAA catabolic pathway.
Contact EDITGENE today to design your custom CRISPR model for branched-chain amino acid catabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| BCKDK Knockout HEK293 Cell Line | EDJ-KQ1127 | Human | 10295 | Details Get a Quote |
| HIBADH Knockout HEK293 Cell Line | EDJ-KQ2273 | Human | 11112 | Details Get a Quote |
| BCKDHA Knockout HEK293 Cell Line | EDJ-KQ3457 | Human | 593 | Details Get a Quote |
| BCAT2 Knockout HEK293 Cell Line | EDJ-KQ4126 | Human | 587 | Details Get a Quote |
| BCKDHB Knockout HEK293 Cell Line | EDJ-KQ4129 | Human | 594 | Details Get a Quote |
| DBT Knockout HEK293 Cell Line | EDJ-KQ4430 | Human | 1629 | Details Get a Quote |
| ECHS1 Knockout HEK293 Cell Line | EDJ-KQ4495 | Human | 1892 | Details Get a Quote |
| IVD Knockout HEK293 Cell Line | EDJ-KQ5012 | Human | 3712 | Details Get a Quote |
| ALDH6A1 Knockout HEK293 Cell Line | EDJ-KQ5224 | Human | 4329 | Details Get a Quote |
| SLC25A44 Knockout HEK293 Cell Line | EDJ-KQ6688 | Human | 9673 | Details Get a Quote |
| HIBCH Knockout HEK293 Cell Line | EDJ-KQ8497 | Human | 26275 | Details Get a Quote |
| ACAD8 Knockout HEK293 Cell Line | EDJ-KQ8651 | Human | 27034 | Details Get a Quote |
| PPM1K Knockout HEK293 Cell Line | EDJ-KQ11491 | Human | 152926 | Details Get a Quote |
| MCCC1 Knockout HEK293 Cell Line | EDJ-KQ14215 | Human | 56922 | Details Get a Quote |
| MCCC2 Knockout HEK293 Cell Line | EDJ-KQ14216 | Human | 64087 | Details Get a Quote |
Displaying Records 1 To 15 Of 61 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About branched-chain amino acid catabolic process
What is GO:0009083?
GO:0009083 is the Gene Ontology term for the branched-chain amino acid catabolic process, describing the breakdown of leucine, isoleucine, and valine.
What genes are involved in branched-chain amino acid catabolic process?
Key genes include BCAT1, BCAT2, BCKDHA, BCKDHB, DBT, DLD, BCKDK, PPM1K, IVD, ACADSB, MCCC1, and MCCC2 [1, 4].
Why is BCAA catabolism important for health?
It disposes of essential BCAAs, provides energy, and its dysfunction is linked to insulin resistance, heart failure, obesity, and type 2 diabetes [1, 2, 3, 5].
How is BCAA catabolism regulated?
It is regulated by reversible phosphorylation of the BCKDH complex via BCKDK and PPM1K, as well as by hormonal and nutritional signals [1, 4].
What diseases are associated with impaired BCAA catabolism?
Heart failure, insulin resistance, type 2 diabetes, diabetic retinopathy, and inflammatory conditions [1, 2, 3, 6, 8].
What is the role of BCAT1 in disease?
BCAT1 activation reprograms BCAA metabolism and epigenetically promotes inflammation in diabetic retinopathy.
How can CRISPR help study BCAA catabolism?
CRISPR knockout, knock-in, and overexpression models allow precise manipulation of BCAA catabolic genes to study their causal roles in disease [4, 6].
What is the BCKDH complex?
The BCKDH complex is a multienzyme complex that catalyzes the rate-limiting step of BCAA catabolism, and its activity is regulated by phosphorylation [1, 4].
Does BCAA catabolism affect the immune system?
Yes, BCAA catabolism promotes M2 macrophage polarization and modulates inflammatory responses.
What experimental models are used to study BCAA catabolism?
Common models include knockout mice, cell lines with CRISPR edits, and human iPSC-derived cells, combined with metabolomics and enzyme assays [1, 4, 5].
Conclusion
The branched-chain amino acid catabolic process (GO:0009083) is a fundamental metabolic pathway with far-reaching implications for human health. Its dysregulation is a common thread in heart failure, insulin resistance, type 2 diabetes, and inflammatory diseases. Advances in CRISPR-based models and metabolomic technologies are enabling researchers to dissect the precise roles of individual enzymes and regulatory nodes. Targeting this pathway holds promise for novel therapeutic interventions in metabolic and cardiovascular disorders.
References
- 1. Sun H et al.. 2016. Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure.. Circulation 133(21):2038-49 PMID: 27059949
- 2. Newgard CB et al.. 2009. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance.. Cell Metab 9(4):311-26 PMID: 19356713
- 3. White PJ et al.. 2021. Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street.. Mol Metab 52:101261 PMID: 34044180
- 4. Mansoori S et al.. 2025. Branched-chain amino acid metabolism: Pathophysiological mechanism and therapeutic intervention in metabolic diseases.. Obes Rev 26(2):e13856 PMID: 39455059
- 5. Vanweert F et al.. 2022. Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes.. Nutr Diabetes 12(1):35 PMID: 35931683
- 6. Li Y et al.. 2020. Branched chain amino acids exacerbate myocardial ischemia/reperfusion vulnerability via enhancing GCN2/ATF6/PPAR-α pathway-dependent fatty acid oxidation.. Theranostics 10(12):5623-5640 PMID: 32373236
- 7. Lu M et al.. 2024. Branched-chain amino acid catabolism promotes M2 macrophage polarization.. Front Immunol 15:1469163 PMID: 39582859
- 8. Wang J et al.. 2025. BCAT1 Activation Reprograms Branched-Chain Amino Acid Metabolism and Epigenetically Promotes Inflammation in Diabetic Retinopathy.. Invest Ophthalmol Vis Sci 66(6):59 PMID: 40530920
